Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADH-1 in N-cadherin positive advanced solid tumors
NCT00264433Phase 2Completed
- Sponsor
- Adherex Technologies
- Countries
- 2
01
Overview
A Phase 2 trial of ADH-1 in non-small cell lung cancer (NSCLC), gastroesophageal junction adenocarcinoma, renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), adrenocortical carcinoma (ACC), sponsored by Adherex Technologies. Status: completed.
02
Drugs
ADH-1
03
Conditions
non-small cell lung cancer (NSCLC)gastroesophageal junction adenocarcinomarenal cell carcinoma (RCC)hepatocellular carcinoma (HCC)adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT00264433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00264433.